Evidence map›Paper›PMID 38469569›Full record

ReviewFrontiers in oncology2023

Biopterin metabolism and nitric oxide recoupling in cancer.

Gene Chatman Clark, Alan Lai, Aashri Agarwal, Zheng Liu, Xiang-Yang Wang

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Gene Chatman ClarkDepartment of Biochemistry, Virginia Commonwealth University, Richmond, VA, United States.
Alan LaiSchool of Medicine, Virginia Commonwealth University, Richmond, VA, United States.
Aashri AgarwalCornell University, Ithaca, NY, United States.
Zheng LiuDepartment of Human Molecular Genetics, Virginia Commonwealth University, Richmond, VA, United States.
Xiang-Yang WangDepartment of Human Molecular Genetics, Virginia Commonwealth University, Richmond, VA, United States.
Virginia Commonwealth University · USCornell University · US

Funding

A novel role of IGFBP7 in the microenvironment of hepatocellular carcinomaR01CA240004 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SARKAR, DEVANAND, WANG, XIANG-YANG SHAWN · 2019 to 2023
$2.4M
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapyR01CA229812 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FANG, XIANJUN, WANG, XIANG-YANG SHAWN · 2019 to 2023
$2.0M
NCI NIH HHS R01 CA229812NCI NIH HHS R01 CA240004
6 · The paper itself

Abstract

Tetrahydrobiopterin is a cofactor necessary for the activity of several enzymes, the most studied of which is nitric oxide synthase. The role of this cofactor-enzyme relationship in vascular biology is well established. Recently, tetrahydrobiopterin metabolism has received increasing attention in the field of cancer immunology and immunotherapy due to its involvement in the cytotoxic T cell response. Past research has demonstrated that when the availability of BH4 is low, as it is in chronic inflammatory conditions and tumors, electron transfer in the active site of nitric oxide synthase becomes uncoupled from the oxidation of arginine. This results in the production of radical species that are capable of a direct attack on tetrahydrobiopterin, further depleting its local availability. This feedforward loop may act like a molecular switch, reinforcing low tetrahydrobiopterin levels leading to altered NO signaling, restrained immune effector activity, and perpetual vascular inflammation within the tumor microenvironment. In this review, we discuss the evidence for this underappreciated mechanism in different aspects of tumor progression and therapeutic responses. Furthermore, we discuss the preclinical evidence supporting a clinical role for tetrahydrobiopterin supplementation to enhance immunotherapy and radiotherapy for solid tumors and the potential safety concerns.

Indexed as

cancerimmunometabolismimmunotherapynitric oxide synthaseradiotherapyS-nitrosylationtetrahydrobiopterinvascular normalization

Identifiers

PMID38469569
PMCPMC10925643
OpenAlexW4392145926

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.